IASLC Global Survey on Molecular Testing in Lung Cancer
As part of a project aiming to gain more information about the prevalence and practices of molecular testing in lung cancer patients throughout the world, we invite IASLC members, health care professionals and others interested to take this survey. At the end of survey, you will receive the survey link by email, which we invite you to please share with your colleagues, in society newsletters and your professional networks.
Your participation is very important in order for us to understand the current status of molecular testing in lung cancer as well as the regional challenges and barriers to implementation.
The results will be presented at an upcoming IASLC meeting and will be submitted for publication in the official journal of the IASLC, the Journal of Thoracic Oncology. Moreover, the data will support the design of strategies with the goal of helping regions and countries overcome barriers to molecular testing in lung cancer patients.
All respondents will be entered into a drawing to win free attendance (five total) to the IASLC 20th World Conference on Lung Cancer in Barcelona, Spain September 7-10, 2019.
If you have any questions about survey, or if you wish to contact the IASLC about this important activity, please feel free to contact us via email at email@example.com or dial +1.720.598.1949.
AstraZeneca has provided a sponsorship grant towards this independent program.